Last reviewed · How we verify
MOD-5014
At a glance
| Generic name | MOD-5014 |
|---|---|
| Sponsor | OPKO Health, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B (PHASE1)
- A Single-dose, Dose-escalation Study of a Long-acting MOD-5014 in Healthy Adult Male (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MOD-5014 CI brief — competitive landscape report
- MOD-5014 updates RSS · CI watch RSS
- OPKO Health, Inc. portfolio CI